Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ BIT Mining Limited Launches DOLAI, a USD-backed Stablecoin on Solana, Expanding in AI-Powered Financial... (PR Newswire) +++ BIT MINING Aktie +3,82%

HALOZYME Aktie

 >HALOZYME Aktienkurs 
62.34 EUR    +0.2%    (Tradegate)
Ask: 62.28 EUR / 81 Stück
Bid: 61.68 EUR / 90 Stück
Tagesumsatz: 40 Stück
Realtime Kurs von 8 bis 22 Uhr!
HALOZYME Aktie über LYNX handeln
>HALOZYME Performance
1 Woche: +6,5%
1 Monat: +26,2%
3 Monate: +31,2%
6 Monate: +13,5%
1 Jahr: +12,2%
laufendes Jahr: +37,5%
>HALOZYME Aktie
Name:  HALOZYME THERAPEUTICS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US40637H1095 / A0DLHS
Symbol/ Ticker:  RV7 (Frankfurt)
Kürzel:  FRA:RV7, ETR:RV7, RV7:GR
Index:  -
Webseite:  https://halozyme.com/
Profil:  Halozyme Therapeutics Inc. is a biopharmaceutical ..
>Volltext..
Marktkapitalisierung:  7271.42 Mio. EUR
Unternehmenswert:  8087.37 Mio. EUR
Umsatz:  1014.74 Mio. EUR
EBITDA:  658.05 Mio. EUR
Nettogewinn:  479.77 Mio. EUR
Gewinn je Aktie:  3.86 EUR
Schulden:  1299.21 Mio. EUR
Liquide Mittel:  53.26 Mio. EUR
Operativer Cashflow:  471.59 Mio. EUR
Bargeldquote:  4.08
Umsatzwachstum:  22.72%
Gewinnwachstum:  50.23%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  HALOZYME
Letzte Datenerhebung:  26.08.25
>HALOZYME Kennzahlen
Aktien/ Unternehmen:
Aktien: 116.97 Mio. St.
Frei handelbar: 98.89%
Leerverk. Aktien: -
Rückkaufquote: 6.28%
Mitarbeiter: 350
Umsatz/Mitarb.: 2.5 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: -2.6%
Bewertung:
KGV: 16.66
KGV lG: 12.02
KUV: 7.6
KBV: 25.78
PEG-Ratio: 0.24
EV/EBITDA: 12.29
Rentabilität:
Bruttomarge: 78.17%
Gewinnmarge: 47.28%
Operative Marge: 57.92%
Managementeffizenz:
Gesamtkaprendite: 27.7%
Eigenkaprendite: 179.14%
>HALOZYME Peer Group

Es sind 601 Aktien bekannt.
 
11.08.25 - 17:30
 Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
 
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....
08.08.25 - 17:30
 After Golden Cross, Halozyme Therapeutics (HALO)′s Technical Outlook is Bright (Zacks)
 
Is it a good or bad thing when a stock experiences a golden cross technical event?...
06.08.25 - 20:31
 HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View (Zacks)
 
Halozyme jumps 5.3% on second-quarter earnings and revenue beat, fueled by strong royalty growth, and a raised 2025 outlook....
06.08.25 - 11:48
 Halozyme raises 2025 revenue guidance to $1.355B amid accelerating royalty growth and new product catalysts (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.08.25 - 05:00
 Halozyme (HALO) Q2 EPS Jumps 69% (Fool)
 
Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...
06.08.25 - 02:30
 Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics (Zacks)
 
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers....
06.08.25 - 01:45
 Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates (Zacks)
 
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.20% and +13.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...
05.08.25 - 22:09
 Halozyme Therapeutics Non-GAAP EPS of $1.54 beats by $0.31, revenue of $325.7M beats by $39.78M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.08.25 - 22:03
 HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS (PR Newswire)
 
Total Revenue Increased 41% YOY to $326 million and Royalty Revenue Increased 65% YOY to $206 million Net Income Increased 77% YOY to $165 million; Adjusted EBITDA Increased 65% YOY to $226 million; GAAP Diluted EPS Increased 85% YOY to $1.33; Non-GAAP Diluted EPS Increased 69% YOY to......
23.07.25 - 17:39
 European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma (PR Newswire)
 
DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma SAN DIEGO, July 23, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that......
22.07.25 - 19:45
 Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again (Zacks)
 
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report....
22.07.25 - 14:30
 Halozyme to Report Second Quarter 2025 Financial and Operating Results (PR Newswire)
 
SAN DIEGO, July 22, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and operating results on Tuesday, August 5, 2025, following the close of trading. Halozyme will host a conference call on......
03.07.25 - 17:30
 Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
 
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....
30.06.25 - 22:30
 Halozyme Therapeutics added to Russell 1000 index (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
20.06.25 - 19:18
 Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PR Newswire)
 
SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO, June 20, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European......
16.06.25 - 17:30
 Here′s Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock (Zacks)
 
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....
04.06.25 - 13:00
 Zacks.com featured highlights Sterling Infrastructure, BJ′s Wholesale, Molina Healthcare and Halozyme (Zacks)
 
Sterling, BJ's, Molina, and Halozyme stand tall with robust earnings growth and high interest coverage in June picks....
28.05.25 - 22:06
 Halozyme to Participate at Upcoming Investor Conferences (PR Newswire)
 
SAN DIEGO, May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to participate and host investor meetings at the following investor conferences. Details on the......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der Herr wird denen entgegenkommen, die verstehen, in den Tag hinein zu leben, immer ihre Pflicht tun, mit Ruhe, Würde und Geduld, ohne sich den Kopf heiß zu machen wegen der Dinge, die morgen oder in Zukunft geschehen können. - Papst Johannes XXIII.
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!